Institutional shares held 78.4 Million
3.4K calls
1.9K puts
Total value of holdings $731M
$31K calls
$17K puts
Market Cap $557M
59,698,100 Shares Out.
Institutional ownership 131.3%
# of Institutions 207


Latest Institutional Activity in XNCR

Top Purchases

Q2 2025
Versant Capital Management, Inc Shares Held: 4.59K ($42.9K)
Q2 2025
Massmutual Trust CO Fsb Shares Held: 319 ($2.98K)
Q2 2025
Umb Bank, N.A. Shares Held: 553 ($5.16K)
Q1 2025
Braidwell LP Shares Held: 1.66M ($15.4M)
Q1 2025
Primecap Management CO Shares Held: 9.76M ($91.1M)

Top Sells

Q1 2025
Point72 Asset Management, L.P. Shares Held: 1.02M ($9.55M)
Q1 2025
Russell Investments Group, Ltd. Shares Held: 34.7K ($324K)
Q1 2025
Franklin Resources Inc Shares Held: 42.4K ($395K)
Q1 2025
Barclays PLC Shares Held: 178K ($1.66M)
Q1 2025
Ubs Asset Management Americas Inc Shares Held: 180K ($1.68M)

About XNCR

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.


Insider Transactions at XNCR

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
454K Shares
From 14 Insiders
Grant, award, or other acquisition 279K shares
Exercise of conversion of derivative security 175K shares
Sell / Disposition
211K Shares
From 11 Insiders
Open market or private sale 211K shares

Track Institutional and Insider Activities on XNCR

Follow Xencor Inc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells XNCR shares.

Notify only if

Insider Trading

Get notified when an Xencor Inc insider buys or sells XNCR shares.

Notify only if

News

Receive news related to Xencor Inc

Track Activities on XNCR